Reading between the lines in the MD&A 1Q26: Ratchaphruek Hospital Public Company Limited (RPH)

Reading between the lines in the 1Q26 Management Discussion and Analysis of Ratchaphruek Hospital Public Company Limited (RPH): Revenue down 5.5%. Net profit down 32.6%. And a Bt100m buyback authorized for up to 20.45 million shares, with just 8,500 repurchased so far.

The numbers

Revenue eases as inpatient volumes soften

Ratchaphruek Hospital operates a private hospital in Khon Kaen that provides specialist medical and surgical care and is expanding into plastic surgery services through its subsidiary, Kaen Pha-nga Co., Ltd. In 1Q26, total revenue fell 5.5% YoY to Bt272m, as lower outpatient and inpatient volumes, particularly weaker inpatient numbers and bed occupancy, pulled inpatient revenue’s share of the hospital total down to 58.8% from 61.6% a year earlier.

Margins compress as the cost ratio climbs

Gross margin fell to 30.7% in 1Q26 from 34.6% in 1Q25, as hospital operations costs held roughly flat while hospital revenue declined, pushing the cost ratio to 69.3% of hospital revenue from 65.4%. Distribution costs and administrative expenses rose 5.8% YoY to Bt48m. Net profit fell 32.6% YoY to Bt29m, with a net margin of 10.8% versus 15.1% in 1Q25, and earnings per share were down 25.0% to Bt0.06.

Liabilities climb on subsidiary construction payables

Total assets rose 4.0% to Bt1,984m, driven by a 5.7% rise in property, plant, and equipment to Bt1,389m as buildings under construction increased at the plastic surgery hospital subsidiary. Total liabilities rose 24.0% to Bt239m from Bt193m at FY25, driven by higher construction payables at the subsidiary and increased employee benefits provisions, while equity rose 1.7% to Bt1,745m and cash rose Bt16m to Bt296m.

What the numbers don’t show

Comparing the FY25 MD&A with 1Q26, a couple of things stand out.

A Bt100m buyback authorized for 20.45m shares; 8,500 repurchased so far

The FY25 MD&A disclosed that the Board approved a second share repurchase program for financial management purposes on 8 January 2026, with a budget of up to Bt100m for as many as 20.45 million shares, up to 3.75% of issued shares, a formal authorization rather than a stated intention. The 1Q26 MD&A reports that, as of 9 February 2026, the Company had repurchased 8,500 shares at Bt4.94 each under the program, with no further repurchase figures disclosed for the remainder of the quarter.

A cosmetic surgery hospital was renamed, and its 4Q26 target not repeated

The FY25 MD&A’s Project Progress section stated the Company expects its cosmetic surgery hospital project, elsewhere identified in the same filing as the plastic surgery hospital of subsidiary Kaen Pha-nga Co., Ltd., to be completed and ready for operation within 4Q26, a specific timeline for a project already reflected in construction payables on the balance sheet.

The 1Q26 MD&A discusses the same project, now named the Plastic Surgery Hospital Rajapruk-Kaen Pa Nga project, reporting actual progress of 39.6% against a planned 37.7%, with sanitary and electrical works ahead of schedule and air-conditioning and interior decoration work still in preparation, but it does not restate the expected completion quarter. Neither filing states whether the target has changed.

Click here to read our latest report on RPH.